- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05726344
Lactulose vs. Polyethylene Glycol as Bowel Preparation for Colonoscopy in Adults
Colonoscopy is the gold standard in bowel assessment when there is suspicion of colon and rectum pathology. Bowel cleansing is necessary to ensure an optimal visualization of colonic mucosa, allowing this form of detection and removal of polyps. Nowadays international recommendations have multiple bowel preparations. There are differences among them regarding adherence, tolerance and adverse effects. Lactulose (LAC) is widely used in treating constipation. However, there are some randomized clinical assays using LAC as bowel preparation with excellent results according to bowel preparation and tolerance scales. Adherence to bowel preparation significantly affects the result in the endoscopic study.
Safety of polyethylene glycol (PEG) formulations has been validated in several studies, it presents little severe side effects and the advantage of its applicability to patients with several comorbidities (heart, liver and kidney without water deprivation). However, its main disadvantage lies in the need to ingest large amounts of liquid (3-4L), generating intolerance thereto in 15%-45% of patients.
Bowel cleansing preparation with PEG is widely used in clinical practice. Considering that according to international studies reporting better tolerance and adherence with LAC; it is suggested to compare the level of bowel preparation, tolerance and adherence between two groups with LAC and PEG.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Montevideo, Uruguay
- Hospital de Clinicas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients over 18 years with no bowel surgical procedures
Exclusion Criteria:
- Patients willingly deciding not to enter into the study
- Pregnant women
- Patient with colonic resections and/or ileostomies
- Inflammatory bowel disease
- Colonic optimization by prior colonoscopy with poor preparation
- Suspected intestinal occlusion or perforation, intussusception
- Patient with melenas
- Oral iron intake in the past 10 days
- Emergency colonoscopy
- Hypersensitivity to any of the components comprised in preparations.
- Diabetics
- Chronic kidney disease in dialysis
- Uncorrected severe dystonias
- Severe psychiatric illness (schizophrenia)
- Low IQ to understand bowel preparation
- Severe constipation (< 1 weekly stool)
- Chronic diarrhea with high rate (≥ 4 daily evenly loose consistency stools for more than 4 weeks)
- Unbalanced heart diseases (ischemic cardiopathology, congestive heart failure, unstable angina, arrhythmias and untreatable high blood pressure)
- Ascites
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lactulose group
Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed. The day before the study, the group receiving lactulose shall take 4 tablets of Bisacodyl (5 mg) the day before the study at 6pm. Then, at 8pm a bottle of 250 mL (162.5g lactulose) of lactulose shall be dissolved in 600 mL of water and all contents (850 mL) shall be taken in 2 hours. At 10pm they have to drink 2 liters still water. |
4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g
lactulose) of lactulose + 600 mL of water + 2 L of water
Other Names:
|
Experimental: Polyethylene glycol group
Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed. The day before the study, the group receiving polyethylene glycol (PEG) should take 4 tablets of Bisacodyl (5 mg) at 4pm. Then, at 6pm, 3 bottles of PEG (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) shall be dissolved in 3 liters of water (1 bottle per liter) and they shall take half the preparation, that is 1 liter and a half in 2 hours. At 10pm they shall take the remaining contents in 2 hours. |
4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare lactulose vs. Polyethylene Glycol as bowel cleansing preparation for colonoscopy
Time Frame: 6 months
|
Compare the level of bowel preparation (by Boston Bowel Preparation Scale) between two groups with lactulose and Polyethylene Glycol. The minimum and maximum value is 0 and 9, respectively. A proper preparation is consider a Boston Bowel Preparation Scale ≥ 2 scores in each colonic segment. Unsuitable preparation a Boston Bowel Preparation Scale < 2 scores in any of the segments. Score 0: is considered a segment of unprepared colon with mucosa that cannot be observed given the presence of solid stool which does not disappear after cleansing. Score 1: part of the colonic mucosa is observed; other areas cannot be suitably assessed given the presence of staining, residual matter and/or opaque liquid. Score 2: little remaining residual matter and small matter fragments which do not prevent correct visualization of colonic mucosa in said segment. Score 3: colonic mucosa which can be entirely observed with no residual matter nor small fragments of matter and opaque liquid. |
6 months
|
Establish Boston Bowel Preparation Scale inter and intra-observer variability
Time Frame: 7 months
|
Two researchers shall review the endoscopic study videos and they shall complete the Boston Bowel Preparation Scale inter-observer questionnaire. Results obtained by the endoscopist in charge of the study and the observers shall be compared so as to establish inter-observer variability. Researchers shall analyze one month later again all colonoscopies recorded thus establishing Boston Bowel Preparation Scale of each endoscopy. Then results previously established shall be compared so as to establish intra-observer variability. The minimum and maximum value is 0 and 9, respectively. A proper preparation is consider a Boston Bowel Preparation Scale ≥ 2 scores in each colonic segment. Unsuitable preparation a Boston Bowel Preparation Scale < 2 scores in any of the segments. |
7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess tolerance between lactulose and Polyethylene Glycol.
Time Frame: 6 months
|
To assess tolerance it will be considered: good tolerance those patients with 3 or less symptoms with no major criterion; regular tolerance those patients with 4-5 symptoms, without major criterion and bad tolerance those patients with 6 or more symptoms or 1 or more major criteria.
|
6 months
|
Assess adherence between lactulose and Polyethylene Glycol.
Time Frame: 6 months
|
To assess adherence it shall be assessed if the preparation was completed as well as the will to repeat the same preparation in the future.
|
6 months
|
Assess side effects between lactulose and Polyethylene Glycol.
Time Frame: 6 months
|
To assess side effects of both preparations that will be considered: nausea, vomiting, abdominal pain or bloating, sickness, lipothymia, palpitations, precordial pain, insomnia, anal pain or burning, dry mouth, tinnitus, unpleasant taste.
|
6 months
|
Establish colonoscopy global adenoma detection rate with lactulose and Polyethylene Glycol.
Time Frame: 6 months
|
It correspond to the number of adenomas/adenocarcinomas (histological diagnosis) divided by the total number of colonoscopies performed times 100.
|
6 months
|
Establish colonoscopy cecal intubation rate in with lactulose and Polyethylene Glycol.
Time Frame: 6 months
|
It correspond to the number colonoscopies visualizing ileocecal valve divided by the total number of colonoscopies performed times 100.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: IGNACIO MORATORIO, MD, Hospital de Clinicas
- Principal Investigator: MARIA B RUSSO, MD, Hospital de Clinicas
- Principal Investigator: FLORENCIA RODRIGUEZ, MD, Hospital de Clinicas
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7477252
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colonoscopy
-
Borland-Groover ClinicValley Medical Products, LLC is paying for the study and is the sponsor....CompletedColonoscopy | Screening Colonoscopy | Surveillance ColonoscopyUnited States
-
Josue AliagaCompleted
-
Endostart srlCompleted
-
Hospital Central Norte PEMEXCompletedPerformance of Colonoscopy | Tolerance of ColonoscopyMexico
-
VA Office of Research and DevelopmentVA Palo Alto Health Care System; VA Northern California Health Care SystemCompletedWater Exchange Colonoscopy | Unsedated Colonoscopy | Cap | Colonoscopy PainUnited States
-
Rambam Health Care CampusUnknownInadequate Preparation for Colonoscopy; Personalized Colonoscopy PreparationIsrael
-
Dalin Tzu Chi General HospitalCompletedColonoscopy | Intubation Time | Cap-assisted ColonoscopyTaiwan
-
Valduce HospitalCompletedUnsedated Colonoscopy | Warm Water | CO2 ColonoscopyItaly
-
Kartal Kosuyolu Yuksek Ihtisas Education and Research...UnknownColonoscopy | Complete Colonoscopy | Cecum Intubation Time | İleum Intubation TimeTurkey
-
Daewoong Pharmaceutical Co. LTD.Not yet recruiting
Clinical Trials on Polyethylene Glycol 3350
-
Oregon Health and Science UniversityUnknownColonoscopyUnited States
-
Walter Reed National Military Medical CenterCompleted
-
University Hospitals Cleveland Medical CenterNot yet recruitingConstipation | Surgical Procedure, Unspecified | Prolapse; FemaleUnited States
-
Chad R. TracyRecruitingKidney Cancer | Constipation | Prostate CancerUnited States
-
Ascension Genesys HospitalUnknownClostridium Difficile ColitisUnited States
-
Medical University of WarsawCompletedChildren Prior to ColonoscopyPoland
-
University of ChicagoRecruiting
-
Braintree LaboratoriesCompletedColon CancerUnited States
-
University of AarhusRecruiting
-
Nova Scotia Health AuthorityWithdrawnNerve Injury | Peripheral Nerve Injury